593
148195226014562115177
Ces8507936014570127174
Urol10497936014578115180208
2023;12827936014562121178238260
27(3):15677936014562119147205234256
139-15018497936014561113171211264316376
PŘEHLEDOVÉ852207016974156235334409485586692777855
ČLÁNKY1754207016981154252352436525
6.85089601335679
Chang950896013364124176236298
YH,1269896013359131154
Chuang1444896013364124183236296357
CK,1822896013364122148
Pang1990896013359110171232
ST,2243896013354109125
et238989601335592
al.250289601335378100
Prognostic262489801315586142202260319359393415463
value3109898013150100122179232
of336289801315987
TNM3471898013151122206
stage369989801314175125184237
and3958898013150108167
tumor414789801313491180239271
necrosis4439898013159112162193250290311350
for481089801312986118
renal495089801313284142191213
cell5184898013149100123145
carcinoma.850104801314999130177199256314404453472
Kaohsiung13461048013155106164223262283340398457
Journal1827104801313897154186245293316
of2167104801315887
Medical22781048013185138199221269319341
Sciences.26431048013151100122174232281331372391
2011;30581048013154105153194204
27(2):32871048013153103126178204220
59–63.35321048013153102159216267285
7.850119601335668
An9381196013368128
JS,1087119601334093116
Packiam12241196013358110158209236288379
VT,16241196013361120136
Chennamadhavuni17811196013363123178239299352443495557617670721781842867
A,2668119601336892
et2781119601335591
al.2893119601335378101
Patient30151198013155103135158210268300
Characteristics33361198013163120169200250299335386417440479513536584625
and39831198013150107167
Survival41711198013151108139192215264314336
Outcomes45281198013174133166212268358411451
of5001119801315887
Non­51091198013170128187220
‑Metastatic,8501348013133119172205255295329379411433481500
Non‑Clear13741348013170129187220286308361409440
Cell18381348013163114137158
Renal20201348013156109167216238
Cell22821348013163114136158
Carcinoma.24641348013163113144191212270328418467486
Frontiers2974134801315179136194226248301332373
in3371134801312381
Oncology.34761348013174133181237260318379427440
2022;39411348013153105154207224
11.4190134801315394106
8.850149601335680
Wagener9551496013393143204259320375411
N,1391149601337296
Edelmann15121496013354115169195286339399459
D,1997149601337392
Benner21141496013360115176236291327
A,2466149601336892
et2584149601335591
al.2700149601335379101
Outcome28271498013174132166212268358411
of3264149801315887
papillary33771498013161111170193215236285316368
versus37711498013150102133174230270
clear4067149801314971124172203
cell42961498013149100123144
renal4466149801313384142191213
cell47051498013149100123144
carcinoma4876149801314998130176198256314403452
varies8501648013150100131153206246
significantly1120164801314163122179201227254302352410441464512
in1656164801312380
non‑metastatic17611648013159117175209299352385435475509559591613661
disease.2446164801316082121174222262315332
Plos2802164801315577135175
One.30011648013173132185202
2017;32281648013153105152196209
12(9).3461164801315499124173199214
9.850179601335674
Warren9421796013392141175210263322
AY,12831796013366116130
Harrison14321796013370122156191216257316375
D.1826179601337290
WHO/ISUP19361798013189156228263285332397450
classification,2405179801314869116155194214239265313361392413470527544
grading2968179801315989138196217273331
and33181798013149105163
pathological35001798013160109140197253276332391412459507529
staging4048179801314074122180201257315
of4382179801315785
renal4486179801313282139186207
cell4712179801314998120141
carcinoma:4872179801314897127172193249306394441458
standards850194801314176125183242291322380420
and12941948013150107167
controversies.14851948013149105163195227284332384415456477530570590
World20991948013190145177200259
Journal2382194801313896154186245293316
of2722194801315887
Urology.2833194801316899156179237297346359
2018;32161948013154105153200217
36(12):34571948013153106134181226252268
191326.3750194801315398146191240291310
10.8502096013356107129
Lin1006209601335277137
TF,11702096013355109121
Lin1318209601335277137
WR,14822096013393152177
Chen16862096013364124179240
M,19532096013388112
et2092209601335592
al.2211209601335378101
Compare23402098013163119208268318349401
fuhrman2769209801312887145176266315373
nuclear31702098013159116165187239288319
and35172098013150107167
chromophobe37122098013149107138194284342403461520580634
tumor4374209801313492181239271
grade4673209801316091141200253
on49542098013159117
chro‑50992098013150107138195230
mophobe8502248013190148209267326386440
RCC.13142248013156118175194
Open15332248013173134188246
Medicine.18032248013186139199221269291349402419
2019;22462248013153105153198216
14(1):24862248013154100129176197213
336–42.27232248013154104156214270319337
11.8502396013357101119
Ohashi10002396013376137190233293318
R,1349239601336085
Martignoni14652396013388142177216241302363423484509
G,2006239601337195
Hartmann21322396013372125160200291343404464
A,2628239601336792
et2751239601335592
al.2874239601335378101
Multi‑institutional30082398013186143166199221254278335375410432465523557579637695744767
re‑evaluation3807239801313284119174223273296353402434456514573
of4412239801315987
prognostic4531239801316193150210268327367402424472
factors5035239801312980129165221253294
in850254801312381
chromophobe9572548013149107138194284342403461520580634
renal1617254801313384142191213
cell18562548013150100123145
carcinoma:2027254801314999130177199256314404453470
proposal2524254801316092149209268308359381
of2931254801315987
a30442548013150
novel31212548013159117165217240
two‑tiered33872548013134116173208242264316348399460
grading3873254801316091141200222280339
scheme.4239254801314189147200289342360
Virchows4625254801315680111158216274352393
Archiv.5044254801316496143200222271285
2020;8502698013154105155206225
476(3):10992698013154102150177228253270
409–18.13932698013153108162219265311331
12.8502846013356104127
de9992846013362117
Peralta‑Venturina11382846013359112147200226261315349409460521556616651676737789
M,19492846013388112
Moch20842846013388149198258
H,2365284601337195
Amin24822846013367158183243
M,27472846013389113
et2882284601335591
al.2996284601335378100
Sarcomatoid31202848013151101132179235324373405461484543
differentiation3686284801316081111140192224275333365387435467489547606
in4315284801312380
renal4418284801313284142191213
cell46542848013149100122144
carcinoma4821284801314999130177198256314404453
-52962848013133
A8502998013164
study938299801314176134193241
of1204299801315886
10113152998013153100148
cases.1487299801314999139192232251
American17632998013164153206238260309358416
Journal2203299801313896154186244293315
of2543299801315886
Surgical26542998013151107139196218267316338
Pathology.30172998013155103135193251274332393441455
2001;34962998013153105160208218
25(3):37382998013154107133183208225
275–84.39872998013154103153208263318336
13.8503146013356105126
Lee9963146013352106162
SE,11773146013355107130
Byun13273146013359111172233
SS,15793146013355107129
Oh17283146013376137
JK,18853146013341100126
et2031314601335591
al.2142314601335378100
Significance2263314801315172131189210236263311361419467518
of2802314801315886
macroscopic29093148013190139187219275315364420480502551
tumor3480314801313492180239271
necrosis37713148013159112161193249289311349
as4141314801315089
a42513148013150
prognostic4321314801316193149210267325365400422470
indicator4812314801312380139161209259291347379
for5211314801312986118
renal850329801313284142191213
cell10873298013149100122144
carcinoma.1255329801314999130177199256315404453472
Journal1751329801313896154186245293316
of2091329801315887
Urology.2202329801316899156179237297346359
2006;25853298013154105161215232
176(4):2841329801315498146173223248265
1332–7.3130329801315498148197249296303
14.8503446013356106128
Vasudev10043446013362112154214275330382
NS,14133446013372125148
Wilson15873446013393120145187247308
M,19223446013388112
Stewart2060344601335488142222275310349
GD,24363446013371144163
et2626344601335591
al.2743344601335379101
Challenges28723448013163120169191213266324383436476
of3375344801315987
early34893448013154102133156204
renal3720344801313384142191213
cancer3960344801314999157205256288
detection:42753448013160113146197246282304362421438
symptom4740344801314190180240273329418
pa‑51853448013161111144
tterns850359801313470121153212251
and11313598013150108167
incidental1328359801312380129151210263321352402424
diagnosis1782359801316082130189247305345367406
rate2217359801313383115166
in2413359801312380
a25233598013150
multicentre26033598013190147169203225273324382413445497
prospective3129359801316193150190249303352389411460512
UK36713598013168122
cohort38233598013149105163222254291
of4144359801315886
patients42603598013161111143165218276307349
presenting4639359801316193144184237295327349407466
with51353598013179102135193
suspected850374801314197137196250299336387447
renal1321374801313284142191213
cancer.1558374801314999157205256287301
Bmj18833748013156145167
Open.20743748013174135189247266
2020;23643748013153105154206224
10(5).26123748013154101130181208223
15.8503896013356105126
O’Brian1002389601337699158194220272332
D,1360389601337493
Prunty1479389601335993153214249303
M,18093896013388112
Hill1947389601337297122147
A,2121389601336792
Shoag22393896013354114174227289
J.2554389601334062
The26433898013151111164
Role28343898013156114137190
of3051389801315887
C‑Reactive3165389801316381138191239287323346395447
Protein3639389801315585142174225247305
in3971389801312380
Kidney,4078389801315579138196249297310
Bladder,4415389801315578127186246299330343
and47853898013150108167
Prostate4979389801315686143183217267299350
Cancers.8504048013163112170219270301342362
Frontiers1236404801315079136194226248301332373
in1633404801312381
Immunology.17384048013123112201258316374397455515564577
2021;23394048013154106155202213
12.2576404801315498116
16.8504196013356107130
Teishima10024196013355103128170231256347399
J,1424419601334062
Kobatake15084196013360118181234269323373427
K,1957419601336086
Shinmei20654196013354115140200291346371
S,2459419601335477
et2558419601335592
al.2672419601335379101
The27974198013151111164
effect2984419801315483112165214250
of3257419801315987
kinetics3368419801314670128181214236284326
of3717419801315987
C‑reactive3827419801316382114166214263299321370422
protein4272419801316193150182233255312
in4608419801312380
the4712419801313392145
prediction4880419801316193144204226275311333391449
of850434801315987
overall9664348013158106158190240262284
survival1278434801314198129182205254304326
in1633434801312380
patients17424348013161111143165217275307349
with21204348013179102135193
metastatic23424348013190143176226265300349382404452
renal2823434801313284142190213
cell30644348013149100123144
carcinoma3237434801314999130177199256315404453
treated3719434801313465117165197248308
with40564348013180102136194
tyrosine4278434801313486118175215236294347
kinase4653434801314771128177217270
inhibitor.4952434801312380138160219242275331363377
Urologic8504498013169100156179237298319368
Oncology‑Seminars12424498013174132181237260318378427460507560649671728777808849
and21154498013150108167
Original23074498013173106128187209267316338
Investigations.2669449801312381128180220255277336384417439496555594614
2017;33074498013154105153196210
35(11).35414498013153103129176217237252
17.8504646013356104115
Jabs990464601334193155198
WJ,12134646013393128149
Busse13874646013360120163205260
M,16734646013388112
Kruger1810464601336097157219273309
S,2144464601335577
et2246464601335592
al.2363464601335378101
Expression24904648013151101161193244285324346403462
of2978464801315887
C‑reactive3091464801316281114165213262298320369421
protein3538464801316193149182233255312
by38764648013161108
renal4010464801313284142191213
cell42494648013149100122144
carcinomas4419464801314999130177198256314404453493
and49374648013150108168
una‑51314648013158116164198
ffected850479801313060112161197248309
surrounding1183479801314197128161217275333392414472531
renal1738479801313384142191213
tissue.197547980131345695135191244262
Kidney2261479801315478138195248296
International.2581479801312381113164195254303335357415473522544563
2005;31684798013153105160212226
68(5):34184798013154108136187213230
2103–10.36724798013154101148198253299347364
18.8504946013356107130
Tamura10094946013355100191251286339
K,1378494601335985
Matsushita14924946013389142177221280323383408444498
Y,2019494601336075
Watanabe21234946013393143179232292344406462
H,2614494601337295
et2739494601335591
al.2859494601335479101
Feasibility29914948013151102150190211271293315337370421
of3443494801315887
the3560494801313492145
ACL37354948013165124172
(albumin,393749480131297597156215304325383401
C‑reactive4368494801316381114165213262298320370421
protein4820494801316092149181232254312
and51624948013150108167
lactate850509801312372121157206239289
dehydrogenase)11615098013160112171217275306363423476534583622675701
model18835098013190148209262284
as2188509801315090
a22995098013150
novel23705098013159118166218240
prognostic2632509801316092149209267325365400422470
tool3123509801313490149172
in3317509801312380
patients34185098013161111143165218276307349
with37885098013180102136194
metastatic40035098013190143176226266300350382404452
renal4477509801313284141190212
cell47115098013149100122144
carcinoma4876509801314999130177199256314404453
previously850524801316193144193216274332371393441
receiving1318524801313284133184206255278336395
first‑line174052480131275485126160189213234292345
targeted2112524801313484115173226259310370
therapy.2509524801313492146177227286334347
Urologic28835248013169100157180238298320368
Oncology‑Seminars32785248013174133182238261319379427460507560649671729777809850
and41555248013150108167
Original43495248013174107129188210268316339
Investigations.4715524801312381128180220255277336384417439496555594614
2020;8505398013154105155206225
38(1).10995398013153106134181201216
19.8505546013356106125
Tamura10055546013355100191251286339
K,1374554601336085
Ando14905546013367127189249
R,1770554601335984
Takahara18845546013355100151205265318353406
K,2320554601336085
et2436554601335591
al.2557554601335379101
Development26905548013171125174225248306366456509567599
of3320554801315987
novel34385548013159118166218240
ACN37105548013164123192
(albumin,393355480131297597157215304326383401
C‑reactive4365554801316382115166214263299321370422
protein4819554801316092149181232254312
and51625548013150108167
neutrophil‑to‑lymphocyte8505698013159112169203235291351410432454487520576611635683773833891950999105010871138
ratio)2011569801313282114136194219
prognostication2253569801316092149209267325365400422470520552574632690
model29665698013190148208261284
for3272569801312986118
patients34135698013160110142164217275307348
with37845698013179102135193
metastatic39995698013190144177226266301350382404453
renal4474569801313384142191213
cell47095698013149100123144
carcinoma4876569801314999130177198256314404453
receiving850584801313284133184206255278336395
first‑line127358480131275384125160189213234292345
molecular‑targeted16465848013190148171224274331353402433462495545576634687720771831
therapy.2505584801313492145177227286333347
Urologic28805848013169100156179237297319368
Oncology‑Seminars32765848013173132181237260318378427459507560649671728777808849
and41535848013150108167
Original43485848013174106129188210267316338
Investigations.4714584801312481129180221255277336385417439497555595615
2021;8505998013154105155202212
39(1).10875998013153103132179199214
20.8506146013356111133
Yilmaz1003614601336086111202254302
H,1325614601337295
Yilmaz1440614601336086111202254302
A,1762614601336792
Demirag18746146013374129221246281334395
G.2289614601337196
Prognostic2406614801315586142202260319359393415463
significance2890614801314163122180201227254302352410458509
of3420614801315987
hemoglobin‑to‑red35286148013159112201260320342400460483540574607663698731782842
cell43916148013149100123145
distribution4557614801316081120155187209269327360382440499
width50776148013179102161194252
ratio850629801313282115137194
in1068629801312381
patients11736298013161111143165218275307349
with15466298013179102135193
metastatic17636298013191144177226266301350382405453
renal2240629801313284142191213
cancer.2477629801314999156205256287301
Future28026298013151106140197229280
Oncology.31066298013174133182238261319379427441
2021;35716298013154105155202212
17(29):3807629801315498121173224250267
3853–64.40986298013154106157207262319375393
21.8506446013358110128
Basmaci10106446013361116160253307357383
I,1425644601332751
Celik15096446013365120147172225
S,1766644601335579
Sefik18786446013355112141171223
E,2134644601335578
et2245644601335694
al.2371644601335481104
Evaluation25096448013152102153176235285319342401461
of3004644801315989
the3126644801313595149
Prognostic3309644801315688146208268327369405428477
Value38206448013157105129187242
of4095644801316089
Preoperative4218644801315688141202264319352403436460510564
Neutrophil­48156448013172127186220253311373434456479514
‑tolymphocyte850659801313366122145193283343402460509560598649
Ratio15236598013155105137159217
in1764659801312380
Renal18686598013156109167216238
Cell21306598013163114136158
Carcinoma.23126598013163113144191212270328418467486
Journal2822659801313896154185244293315
of3161659801315987
Urological32726598013169100156180238298320368418440
Surgery.37366598013151108139197250281333346
2019;41066598013154106153198217
6(3):4347659801315381132157173
218–45456598013153100147203
24.47726598013154102120
22.8506746013356112135
Suppiah10096746013354113175238263315376
R,1409674601335984
Shaheen15176746013354114166227282337398
PE,19396746013359111133
Elson2096674601335479122182243
P,2363674601335868
et2455674601335591
al.2570674601335378101
Thrombocytosis26966748013151111142199288348407457508545601641662701
as3422674801315090
a35366748013150
prognostic3611674801316092149209267325365400422470
factor4106674801312979128164220252
for4383674801312986118
survival4525674801314198129182205254304326
in4876674801312380
patients49816748013161111143165217275307349
with8506898013179102135193
metastatic10676898013191144177226266301350382405453
renal1544689801313284142191213
cell17816898013149100122144
carcinoma.1949689801314999130177199256314404453472
Cancer.24456898013163113170219270301315
2006;27846898013154106161215232
107(8):30406898013154101150174225251268
1793–800.3332689801315397148197252307361416434
23.8507046013356112134
Zhang10087046013361121173234295
ND,13277046013373146165
Zhang15177046013361121173233294
HN,18367046013372144167
Zhu20287046013361121180
DQ,22337046013373149173
et2430704601335592
al.2546704601335379101
Prognostic2673704801315586142202260319359393415463
role3162704801313289112165
of3352704801315987
pretreatment3464704801316193145178210261309341431484542574
lactate4063704801312372121157206238289
dehydrogenase43787048013160113171217275306363423476534583623676
in5079704801312381
pa‑51857048013161111144
tients850719801313456109167198240
with11187198013180102136194
metastatic13407198013190143176226266300350382404452
renal1821719801313284142191213
cell20627198013149100123144
carcinoma:2235719801314998130176198256314404453470
a27337198013150
systematic2811719801314291131166217306355387409457
review3297719801313284132155208286
and36127198013150107167
meta‑analysis.38077198013190143176226260309366415437485526547586606
International4441719801312381113164195254303335357415473522544
Journal5013719801313897155186245294316
of850734801315987
Surgery.9617348013151108139197250281333346
2020;13327348013153105154206224
79:15807348013154104123
66–73.17277348013154108166213265283
24.8507496013356109131
Shen10107496013354114169230
J,1269749601334062
Chen13597496013364124179240
Z,1627749601336184
Zhuang17407496013360120180232293354
QF,21237496013375129141
et2293749601335591
al.2413749601335378100
Prognostic2543749801315586142202260319359393415463
Value30367498013156103125182235
of3300749801315987
Serum34177498013151104135194283
Lactate37297498013149100149185234267318
Dehydrogenase40767498013171125183229288319375436489546595635688
in4794749801312380
Renal49047498013155108166215237
Cell51717498013162113136158
Carcinoma:8507648013163112144190212270328418467484
A13587648013164
Systematic1446764801315196137171222311360392414462
Review19337648013155108157180232311
and22687648013150108167
Meta‑Analysis.24597648013186139172222255318376425447495536557596615
Plos3098764801315677135175
One.32977648013174133186203
2016;35247648013153105153199217
11(11).3765764801315394115163204224239